NCT00406211 is a Phase 3 clinical trial of MMRV in Rubella, sponsored by GlaxoSmithKline.

Who is sponsoring NCT00406211?

NCT00406211 is sponsored by GlaxoSmithKline.

What drugs are being tested in NCT00406211?

Interventions in NCT00406211: MMRV, MMR (Priorix®), Varicella (Varilrix®).

What condition does NCT00406211 study?

NCT00406211 studies Rubella, Varicella, Mumps, Measles.

Is NCT00406211 still recruiting?

NCT00406211 is currently completed. Last updated 14 September 2016.

Last reviewed 2016-09-14 · How we verify

NCT00406211

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®.

Completed Phase 3 Last updated 14 September 2016

What this trial tests

Phase 3 trial testing MMRV in Rubella in 398 participants. Completed in 1 December 2004.

Timeline

1 July 2004

Primary endpoint
1 December 2004

1 December 2004

Quick facts

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	398
Start date	1 July 2004
Primary completion	1 December 2004
Estimated completion	1 December 2004
Sites	41 locations across Austria, Germany

Drugs / interventions tested

MMRV — full drug profile →
MMR (Priorix®) — full drug profile →
Varicella (Varilrix®) — full drug profile →

Conditions studied

Rubella — all drugs for Rubella →
Varicella — all drugs for Varicella →
Mumps — all drugs for Mumps →
Measles — all drugs for Measles →

Sponsor

GlaxoSmithKline — full company profile →

Who can join

Adults 12 Months to 18 Months, any sex, with Rubella or Varicella. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Seropositivity rate & antibody titers for MMRV at 1, 2 & 3 year
Occurrence of breakthrough cases & contacts with MMRV disease(s) for 3 years after vaccination

Sponsor's own description

Follow-up to evaluate the immunogenicity and safety of three production lots of GSK Biologicals' MMRV vaccine given as a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' measles-mumps-rubella (MMR) vaccine (Priorix®) and varicella vaccine (Varilrix®) in Germany \& Austria. Blood samples were collected at three time points during the follow-up period (Year 1, 2 \& 3). No new subjects will be enrolled in these follow-up phases of the study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M, Zepp F, Helm K, Maurer H, et al · · 2012 · cited 14× · PMID 21935584 · DOI 10.1007/s00431-011-1569-4

Verify or expand the search:

Other trials of MMRV

Trials testing the same drug.

NCT07406360 — A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, · Phase 3 · not yet recruiting

Other recruiting trials for Rubella

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting

Other GlaxoSmithKline trials

Trials by the same sponsor.

NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00406211 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
Last refreshed: 14 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00406211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing